SORIN-GROUP

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the results of the Perceval CAVALIER Trial and of the Pooled European Multicenter Experience at the 28^th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Milan, Italy.

The CAVALIER multi-center European trial was designed to evaluate the safety and effectiveness of the Perceval valve in a large population requiring aortic valve replacement (AVR) with or without concomitant coronary bypass grafting. There were 658 patients included from 25 selected European centers. The 30-day results, presented today at EACTS by Professor François Laborde, Institut Mutualiste Montsouris, Paris, France, demonstrated the safety of Perceval through excellent hemodynamic, low complication rates, and ease of implant with a reproducible technique in both sternotomy and the less invasive approach.

In a second study presented by Professor Malakh Shrestha, MHH, Hannover, Germany (European multicentre experience with sutureless Perceval valve: Clinical and haemodynamic outcomes up to 5 years in over 700 patients), Perceval demonstrated excellent and stable results at up to five years follow-up. No valve migrations, structural valve degeneration or valve thromboses were observed in the largest patient cohorts ever implanted with sutureless valves. Low early-30-day mortality (1.9%), low major early paravalvular leak (1.4%) and low early stroke (1.6%) rates confirmed the safety of the sutureless valve. Another noteworthy clinical benefit was the extremely low endocarditis rate (0.3%). This is particularly important for patient outcomes as infective endocarditis is a serious and frequently fatal condition, particularly when it occurs on a valve replacement device¹ .

“Even in this elderly patient cohort with 40 percent of patients aged over 80 years old, early and late mortality were very low,” said Shrestha. “The sutureless technique is a promising alternative to stented biological aortic valve replacement.”

The EACTS 2014 Congress was an excellent venue to showcase the economic benefit of Sorin’s innovative solutions.

Professor Bart Meuris, University Hospitals of Leuven, Belgium, presented today favorable health economic data for Perceval sutureless valve compared to traditional stented valves (Carpentier-Edwards Perimount) in a retrospective matched case-control study. Perceval reported lower use of resources, including significantly shorter intensive care unit and hospital stays, significantly shorter intubation time and reduced use of different blood products (packed cells, plasma and platelets).

“The adoption of sutureless technology is growing day by day,” stated Meuris. “This is a clear example of how innovation can improve patient outcomes and provide important savings to the hospital compared to traditional valves”.

The mean total cost of the Perceval group patients compared with Perimount, net of valve costs, was reduced by 27 percent, i.e. a mean reduction of € 8,176 per case. These cost savings were mainly driven by reduced hospital stay costs and significantly lower procedural costs. In summary, patients with Perceval recovered faster than with Perimount, which led to increased hospital savings overall.

“Saving lives with cutting-edge technology is at the heart of everything we do. Because our latest innovations are developed with both optimal patient safety and greater economic value in mind, they are contributing to an overall reduction in healthcare spending,” said Michel Darnaud, President Cardiac Surgery Business Unit, Sorin Group.

The Perceval sutureless biological valve represents one of the latest innovations in heart valve technology from a long line of innovative products designed and manufactured by Sorin Group. The valve is a self-anchoring surgical aortic valve with a unique self-anchoring frame that enables the surgeon to replace the native diseased valve without suturing it into place. Perceval is now implanted in over 8,000 patients in over 250 centers, in 34 countries in the world.

About Sorin Group
Sorin Group (www.sorin.com ) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,500 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.

For more information, please visit www.sorin.com .

¹ McGiffin DC, Galbraith A J, McLachlan G J, et al. Aortic valve infection: risk factors for death and recurrent endocardits after aortic valve replacement. J THORAC CARDIOVASC SURG 1992;104:511-20.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141013005246/en/

Contact:

Gabriele Mazzoletti, Tel: +39 02 69 96 97 85
Mobile: +39 348 979 22 01
Director, Corporate Communications
Sorin Group
e-mail: corporate.communications@sorin.com
or
Francesca Rambaudi, Tel: +39 02 69969716
Director, Investor Relations
Sorin Group
e-mail: investor.relations@sorin.com

Link:

Multimedia Gallery

ClickThru